{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-277952","form_type":"8-K","ticker":"TMDX","cik":"0001756262","company_name":"TransMedics Group, Inc.","filed_at":"2022-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.996171+00:00","generated_at":"2026-06-22T07:11:04.018666+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"TransMedics amends bylaws to incorporate SEC universal proxy rule requirements","bullets":["Board approved Second Amended and Restated Bylaws, effective November 2, 2022.","Amends director nomination procedures to require compliance with SEC Rule 14a-19 (universal proxy).","Shareholders must disclose proxy solicitation intent and notify company if they fail to comply with Rule.","No successor, substitute, or replacement nominees allowed after the nomination deadline."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-277952","json":"https://secwatch.observer/filing/0001193125-22-277952.json","markdown":"https://secwatch.observer/filing/0001193125-22-277952.md","text":"https://secwatch.observer/filing/0001193125-22-277952.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1756262/000119312522277952/0001193125-22-277952-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1756262/000119312522277952/d401238d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T07:11:04.018666+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f6df7307d37fb644d9914a6ec00da5c817f6b2b0","claim":"TransMedics Group, Inc.: Amended Bylaws to update procedural requirements for director nominations reflecting SEC's universal proxy rules and other administrative changes (effective 2022-11-02).","evidence_excerpt":"On November 2, 2022, the Board of Directors (the “Board”) of TransMedics Group, Inc. (the “Company”) approved the Company’s Second Amended and Restated Bylaws (as so amended and restated, the “Amended Bylaws”), effective as of such date.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1756262/000119312522277952/0001193125-22-277952-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2022-11-02"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}